Katarzyna Stepniewska-Fleischer
Wroclaw, DS, Poland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Evaluation of liver fibrosis in HCV-infected patients using two-dimensional shear-wave elastography (2D-SWE) before and after antiviral treatment.
Journal: Journal of ultrasonography
Published: February 13, 2024
Risk of autoimmune hepatitis reactivation in patients with chronic hepatitis C and autoimmune hepatitis treated with direct-acting antivirals.
Journal: Polish archives of internal medicine
Published: February 14, 2019
Effect of comedication on ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin therapy in chronic hepatitis C - a real-world study.
Journal: Clinical and experimental hepatology
Published: January 21, 2019
Evaluation of brain volume alterations in HCV-infected patients after interferon-free therapy: A pilot study.
Journal: Journal of the neurological sciences
Published: December 21, 2018
Visual and brainstem auditory evoked potentials in HCV-infected patients before and after interferon-free therapy - A pilot study.
Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
Published: November 30, 2018
Interferon-free therapy as the cause of white matter tracts and cerebral perfusion recovery in patients with chronic hepatitis C.
Journal: Journal of viral hepatitis
Published: August 01, 2018
Durability of virologic response, risk of de novo hepatocellular carcinoma, liver function and stiffness 2 years after treatment with ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in the AMBER, real-world experience study.
Journal: Journal of viral hepatitis
Published: March 06, 2018
Real-world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER study.
Journal: Alimentary pharmacology & therapeutics
Published: July 04, 2016
Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial.
Journal: Lancet (London, England)
Published: April 04, 2015
Showing 1-10 of 10
Last Updated: 09/26/2026